Drug‐induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab
Citations Over TimeTop 10% of 2015 papers
Abstract
Progressive multifocal leukoencephalopathy (PML) has been identified as a serious adverse drug reaction (ADR) of several immunomodulatory biologicals. In this study, we contrasted the reporting patterns of PML for two biologicals for which the risk was identified at different points in their lifecycle: natalizumab (before reapproval) and rituximab (nine years postapproval). We found that, apart from the differences in clinical characteristics (age, gender, indication, time to event, fatality), which reflect the diversity in context of use, PML reports for natalizumab were more complete and were received sooner after occurrence. This study serves as an important reminder that spontaneous reports should only be used with great caution to quantify and compare safety profiles across products over time. The observed variability in reporting patterns and heterogeneity of PML cases presents challenges to such comparisons. Lumping uncharacterized PML reports together without taking these differences into account may result in biased comparisons and flawed conclusions about differential safety.
Related Papers
- → Natalizumab and Progressive Multifocal Leukoencephalopathy(2010)114 cited
- → Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences(2005)269 cited
- → Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients(2014)13 cited
- → Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting(2015)8 cited
- → Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML(2020)5 cited